Core Viewpoint - The company is actively monitoring policy trends and market demands related to the construction of national digital trade demonstration zones and relevant standard formulation, viewing it as a significant development opportunity for the industry [1] Group 1: Digital Trade and Market Research - The company is conducting research in the digital trade and consumer platform sectors to align with industry developments [1] - The establishment of national digital trade demonstration zones is seen as a crucial opportunity for growth [1] Group 2: Overseas Business Development - The company is focusing on its overseas business as a key development direction, leveraging its professional consulting team and extensive overseas experience [1] - The company aims to provide comprehensive support for Chinese enterprises going abroad, guided by the "Belt and Road" initiative and driven by ecological cooperation [1] - Future efforts will include continuous optimization of profit and cooperation models to achieve breakthrough progress in overseas business [1]

（编辑 任世碧） 证券日报网讯 1月30日，新朋股份在互动平台回答投资者提问时表示，截至目前公司主营业务没有涉及 半导体业务，公司参与设立的基金投资项目涉及多家半导体企业，具体情况请关注公司历年定期报告。 ...

Core Viewpoint - The company has developed the capability to produce micro-cavity display (MED) products and is focusing on optimizing its technology and production processes for both small and medium-sized displays, while establishing partnerships to enhance its technological foundation and market presence [1]. Group 1: Production Capabilities - The company has mastered the entire production process for MED products, including design and manufacturing techniques, and has achieved mass production capabilities for small-sized MED products [1]. - Current production lines are not economically viable for medium to large-sized MED products, prompting the establishment of a pilot line for medium-sized displays in 2022 [1]. Group 2: Technological Development - The company has successfully created multiple samples of black and color MED products, continuously optimizing the design and manufacturing processes [1]. - In 2023, the company received a 20-year long-term licensing agreement for MED patents and proprietary technology from Wuxi Weifeng Technology Co., Ltd., ensuring a stable supply of plasma materials [1]. Group 3: Intellectual Property and R&D - The company has applied for and authorized over 600 patents related to display and touch technologies, reinforcing its technological foundation and creating a high technical barrier for the MED project [1]. - The company is also investing in a new R&D center for innovative display and touch technologies, including high-performance color electronic paper displays and integrated touch display products [1]. Group 4: Financial Investment - In June 2023, the company invested RMB 36 million in Wuxi Weifeng Technology Co., Ltd. to deepen capital cooperation, facilitating the successful implementation of the MED project [1].

Core Viewpoint - The company is focusing on the micro-cavity electronic paper display (MED) project, targeting the mid-to-large size color electronic paper market, which is expected to see significant growth in demand in the coming years [1] Market Potential - The demand for color electronic paper displays is anticipated to grow explosively, with 2023 being recognized as the year of industrial application for global color electronic paper displays, and 2024 marking the start of large-scale applications [1] - Various technologies, including microcapsule/microcup electrophoretic display technology and MED technology, are gradually being introduced to the market, expanding applications from e-book readers and electronic paper tablets to areas like electronic school bags, extended displays, electronic bus stop signs, digital signage, electronic whiteboards, public displays, and outdoor billboards [1] Market Forecast - According to RUNTO, the global electronic paper display terminal market is projected to reach $72.3 billion by 2025, with a compound annual growth rate (CAGR) exceeding 50% [1] - In the electronic paper tablet market, global shipments were 11.02 million units in 2022, expected to exceed 50 million units by 2026, with a CAGR of over 60% [1] Educational Sector Opportunity - The worsening near-sightedness among youth is expected to create rapid development opportunities for electronic paper display products in the education sector, with an anticipated annual demand for over 50 million color electronic paper books globally [1] Pilot Projects - Some cities, such as Shanghai, have begun pilot projects to promote the use of electronic paper technology in electronic bus stop signs [1] Client Resources - The company has established relationships with well-known global brands, including Lenovo, HP, Dell, and ASUS, and is gradually building business relationships with electronic paper terminal manufacturers like Amazon, Onyx, and iFlytek [1] - The MED product's differentiated positioning in applications such as electronic paper tablets, color e-book readers, laptop secondary screens, electronic notebooks, extended displays, and electronic whiteboards is an extension and expansion of the company's existing high-quality client resources [1]

证券日报网讯 1月30日，德明利在互动平台回答投资者提问时表示，公司业绩表现受行业景气度、业务 开拓、研发创新等多重因素综合影响。公司深耕存储行业多年，具备应对行业周期变化做好供应链管控 与库存管理的核心运营能力。公司未来将进一步把握行业发展机遇，依托在存储领域的技术、供应链及 市场布局等核心优势努力提升经营效益，具体业绩情况请以公司披露的定期报告为准。 （编辑 袁冠琳） ...

证券日报网讯 1月30日，三未信安发布公告称，公司预计2025 年度实现营业收入人民币 52，885.91 万 元至 58，174.51万元，与上年同期相比，将增加 5，565.18 万元至 10，853.78 万元，同比增长11.76% 至 22.94%。 （编辑 楚丽君） ...

（编辑 任世碧） 证券日报网讯 1月30日，博瑞医药发布2025年年度业绩预告称，公司预计2025年年度归属于母公司所有 者的净利润4，130万元到6，190万元，与上年同期（法定披露数据）相比将同比减少67.28%到 78.17%。 ...

Group 1 - The core viewpoint of the article highlights that the company's fourth-quarter revenue was low, which negatively impacted its quarterly profit due to the seasonal nature of its main products, antivenom and tetanus immunoglobulin [1] - The company noted that the incidence rates of snake bites and trauma are significantly higher in summer, leading to larger sales volumes in the second and third quarters, while the first and fourth quarters see lower sales [1] - The company is actively seeking quality acquisition targets to promote its external growth strategy, aligning with its development needs and external environmental conditions [1] Group 2 - The company emphasizes its commitment to adhering to information disclosure regulations and will fulfill its disclosure obligations if there are clear acquisition plans that meet the disclosure standards [1] - Relevant information regarding acquisitions will be based on the company's official announcements [1]

Core Viewpoint - Yongmaotai announced an expected increase in net profit for the year 2025, projecting a net profit attributable to the parent company of approximately 60 million to 70 million yuan, representing a year-on-year increase of about 22.49 million to 32.49 million yuan, which corresponds to a growth rate of approximately 59.96% to 86.62% [1] Financial Performance - The projected net profit for 2025 is estimated to be between 60 million and 70 million yuan [1] - This represents an increase of approximately 22.49 million to 32.49 million yuan compared to the previous year [1] - The year-on-year growth rate is expected to be between 59.96% and 86.62% [1]

（编辑 任世碧） 证券日报网讯 1月30日，粤万年青发布公告称，公司于近日收到保荐机构国联民生证券承销保荐有限公 司（简称"国联民生承销保荐"）出具的《国联民生证券承销保荐有限公司关于变更广东万年青制药股份 有限公司持续督导保荐代表人的函》。国联民生承销保荐作为公司首次公开发行股票并在创业板上市的 保荐机构，原委派杜峰先生和陈雨先生担任公司持续督导保荐代表人，法定持续督导期至2024年12月31 日止。截至目前，持续督导期已届满，鉴于公司募集资金尚未使用完毕，国联民生承销保荐对募集资金 相关事项继续履行持续督导职责。现因陈雨先生工作变动，不再负责公司的持续督导保荐工作。为保证 公司持续督导工作的有序进行，国联民生承销保荐决定委派刘一鸣先生接替陈雨先生担任公司的持续督 导保荐代表人，继续履行相关职责与义务。 ...